Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Data from: Colony losses of stingless bees increase in agricultural areas, but decrease in forested areas by Malena Sibaja Leyton (18400983)

“…</p><p><br></p><p dir="ltr">The data are related to the scientific paper “Sibaja Leyton M. et al., (under review) Colony losses of stingless bees increase in agricultural areas, but decrease in forested areas”.</p><p dir="ltr">Data are available as a csv file titled:</p><p dir="ltr">"Sibaja_Leyton_et_al_Dataset_Stingless_Bee_Colony_Losses_in_Latin_America.csv".…”

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

Sleep deprivation increased inflammatory cytokines and decreased corticosterone in the blood. by Weiran Shan (16969688)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

Splenocytes from Tcj2 mRNA LNP—Immunized mice decrease <i>T</i>. <i>cruzi</i> infection <i>in vitro</i>. by Leroy Versteeg (4248760)

A flow diagram of the study entry. by Sakiko Fukui (387048)

Subjects:

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel efficacy (EPHS). by Takafira Mduluza (39754)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS)... by Takafira Mduluza (39754)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)